Trials / Completed
CompletedNCT04702737
A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Amgen · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tarlatamab | Tarlatamab will be administered as an intravenous (IV) infusion. |
Timeline
- Start date
- 2021-06-10
- Primary completion
- 2024-07-22
- Completion
- 2024-07-22
- First posted
- 2021-01-11
- Last updated
- 2025-09-12
- Results posted
- 2025-09-12
Locations
21 sites across 9 countries: United States, Australia, Austria, Belgium, France, Japan, Netherlands, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04702737. Inclusion in this directory is not an endorsement.